Core Viewpoint - The company, Lushang Furuida Pharmaceutical Co., Ltd., has released its semi-annual report for 2025, highlighting its financial performance and operational results, while also announcing significant governance changes, including the cancellation of its supervisory board and the appointment of a new board secretary [5][19]. Group 1: Company Overview - Lushang Furuida Pharmaceutical Co., Ltd. is engaged in the pharmaceutical industry, focusing on the production and sale of skincare products and related materials [4]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period [4]. Group 2: Financial Data - The semi-annual report indicates that the company will not distribute profits or increase capital reserves through stock issuance during this period [3]. - The average selling price of skincare products increased by 2.52 percentage points year-on-year in the second quarter of 2025 [5]. Group 3: Price Changes - The average procurement price of packaging materials decreased by 0.04 yuan per unit, a decline of 5.80% year-on-year in the second quarter of 2025 [6]. - The average procurement price of moisturizers fell by 12.28 yuan per kilogram, a decrease of 2.51% year-on-year [8]. - The average procurement price of active ingredients decreased by 4.34 yuan per kilogram, a decline of 0.75% year-on-year [9]. - The average procurement price of emulsifiers increased by 0.26 yuan per kilogram, an increase of 1.16% quarter-on-quarter [9]. - The average procurement price of oils decreased by 4.05 yuan per kilogram, a decline of 2.00% year-on-year [10]. Group 4: Governance Changes - The company has decided to cancel its supervisory board, with the responsibilities being transferred to the audit committee of the board of directors [19]. - The board of directors has appointed Ms. Dou Qianqian as the new board secretary, with her term aligned with the current board [15][17]. - The company has revised its articles of association and governance systems to comply with the latest legal requirements and improve operational standards [19][21].
鲁商福瑞达医药股份有限公司2025年半年度报告摘要